Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$12.31 CAD
Change Today +0.43 / 3.62%
Volume 6.8K
COM On Other Exchanges
As of 4:00 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

cardiome pharma corp (COM) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/15 - C$13.80
52 Week Low
08/6/14 - C$6.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CARDIOME PHARMA CORP (COM)

Related News

No related news articles were found.

cardiome pharma corp (COM) Related Businessweek News

No Related Businessweek News Found

cardiome pharma corp (COM) Details

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients from heart diseases. It offers BRINAVESS (vernakalant IV) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It has operations in Canada, the United States, and Europe. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.

Founded in 1986

cardiome pharma corp (COM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$650.0K
Chief Financial Officer
Total Annual Compensation: C$275.0K
Chief Operating Officer
Total Annual Compensation: C$240.0K
Corporate General Counsel
Total Annual Compensation: C$248.5K
Compensation as of Fiscal Year 2014.

cardiome pharma corp (COM) Key Developments

Cardiome Pharma Corp. Announces Executive Appointments

Cardiome Pharma Corp. at its AGM held on June 22, 2015, approved the appointment of Mark H. Corrigan and Arthur H. Willms as Directors. Dr. Corrigan is currently the Chairman of the Board of Directors at Epirus Biopharmaceuticals Inc. and was a former Board member of Cubist Pharmaceuticals Inc. W. James O'Shea will serve as Cardiome's new Chairman of the Board of Directors, effective immediately.

Cardiome Pharma Corp.'s Independent Study Finds Intravenous Vernakalant Facilitates Electrical Cardioversion in Patients with Cardioversion Resistant Atrial Fibrillation

Cardiome Pharma Corp. announced that an independent study conducted by investigators at the University of Leipzig Heart Center, Germany, found that intravenous vernakalant facilitated successful electrical cardioversion ("ECV") in patients who had failed to attain sinus rhythm ("SR") following failed electrical cardioversion ("FECV"), or who immediately returned to Atrial Fibrillation ("IRAF") after briefly attaining SR. The study, entitled "Vernakalant-facilitated electrical cardioversion: comparison of intravenous vernakalant and amiodarone for drug-enhanced electrical cardioversion of atrial fibrillation after failed electrical cardioversion" authored by Andreas Müssigbrodt et al. Cardiome Pharma Corp. did not fund the study, design its protocols or have any role in study implementation or analysis. The non-randomized study examined if either of two pharmacologic converting agents, vernakalant or amiodarone, facilitated subsequent ECV in 63 patients with IRAF (n = 44; 70%) or FECV (n = 19; 30%) after consecutive ECV. Patients were assigned to receive either a single dose of vernakalant (n = 33; 52%) or amiodarone (n = 30; 48%) prior to another attempt with ECV at the discretion of the treating physician. Ten minutes after completion of the drug infusion, transthoracic ECV was attempted again with a shock that had the same energy as the previous shock. In the event of another episode of IRAF, no more attempts of ECV were repeated. The study found that 66.7% of the patients in the vernakalant group (22 of 33 patients) were successfully electrically cardioverted after drug infusion compared to 46.7% (14 of 30 patients) of patients treated with amiodarone (P=0.109). Treatment with vernakalant was also listed as a predictor of successful, drug- facilitated ECV based upon the results of a multivariate analysis (OR 0.057, 95% CI 0.006-0.540, P=0.013). In addition, a subgroup analysis found that patients who had undergone previous AF ablation and who were provided vernakalant had a conversion rate of 66.7% (6 of 9 patients) compared to 11.1% (1 of 9 patients) in the same population who were provided amiodarone (P=0.016). The authors concluded that vernakalant "may therefore be considered as a useful agent for facilitated ECV in cardioversion resistant AF." The study did not report any major adverse events.

Cardiome Pharma Corp. Appoints David Dean as Vice President, Business Development and Investor Relations

Cardiome Pharma Corp. announced the appointment of David Dean as vice president, business development and investor relations of the company. Mr. Dean attained an M.Sc. from the University of Ottawa with a focus on Cardiac Physiology as well as an MBA (Finance) from Queens University. On top of his research analyst registrations in the United States, he was also a registered representative.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COM:CN C$12.31 CAD +0.43

COM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $84.05 USD -0.09
Medicure Inc C$3.04 CAD +0.04
Merck & Co Inc $58.70 USD -0.35
Medicines Co/The $31.02 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation COM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.4x
Price/Book 10.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOME PHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at